Abstract: The present invention provides a computerized method and system for detecting modeling content within a model file without rendering the model file, the method and system including loading the model file into a detection engine, the model file including software code therein. In the method and system, the detection engine scans the model file, detecting descriptor terms within software code. The method and system includes generating a description list for the model file based on the plurality of descriptor terms and executing a conversion engine to review the description list relative to a relational database, the conversion engine electronically generating file terms describing the modeling content within the model file based on input from the relational database. Whereby, the method and system generates a content list for the model file based on the file terms, the content list thereby associated with the model file.

Abstract: The present invention provides a computerized method and system for detecting modeling content within a model file without rendering the model file, the method and system including loading the model file into a detection engine, the model file including software code therein. In the method and system, the detection engine scans the model file, detecting descriptor terms within software code. The method and system includes generating a description list for the model file based on the plurality of descriptor terms and executing a conversion engine to review the description list relative to a relational database, the conversion engine electronically generating file terms describing the modeling content within the model file based on input from the relational database. Whereby, the method and system generates a content list for the model file based on the file terms, the content list thereby associated with the model file.

Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.

Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.

Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.

Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.

Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.

Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.

Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.

Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.

Abstract: Disclosed are lyophilized biologically active proteinaceous compositions containing low diol polyalkylene oxide, such as polyethylene glycol, covalently attached to a biologically active proteinaceous substance and combined with the cryoprotectant cyclodextrin.

Abstract: Disclosed are lyophilized biologically active proteinaceous compositions containing low diol polyalkylene oxide, such as polyethylene glycol, covalently attached to a biologically active proteinaceous substance and combined with the cryoprotectant cyclodextrin.

Abstract: Disclosed are lyophilized biologically active proteinaceous compositions containing low diol polyalkylene oxide, such as polyethylene glycol, covalently attached to a biologically active proteinaceous substance and combined with the cryoprotectant cyclodextrin.

Abstract: This invention discloses a composition comprised of nanoparticles having a surface modifier adsorbed on the surface thereof and a cryoprotectant associated therewith, which cryoprotectant is present in an amount sufficient to form a nanoparticle-cryoprotectant composition. A preferred surface modifier is polyvinylpyrrolidone, and a preferred cryoprotectant is a carbohydrate such as sucrose. This invention further discloses a method of making nanoparticles having a surface modifier adsorbed on the surface and a cryoprotectant associated therewith, comprised of contacting said nanoparticles with the cryoprotectant for a time and under conditions sufficient to form a nanoparticle-cryoprotectant composition.

Abstract: Disclosed are lyophilized biologically active proteinaceous compositions containing low diol polyalkylene oxide, such as polyethylene glycol, covalently attached to a biologically active proteinaceous substance and combined with the cryoprotectant cyclodextrin.

Abstract: A method of countng a succession of sheets passing along a flow line (the sheets being normally spaced but including some overlapping sheets), comprises determining the position of a double thickness in relation to the total length of the sheet in the flow direction. A count of two is added to the count of sheets if the double thickness is found to be symmetrically placed in relation to the total length of the sensed "sheet" and has a length consistent with the amount by which two single sheets would have to overlap to have a total length equal to the sensed "sheet" length. If these requirements are not met, depending on the results of the measurements either a count of one is added or an error signal is generated.